Vivesto Ab · OMXSTO:VIVE
Vivesto Ab — Oasmia — Investival Showcase 2020
13 slides from Vivesto Ab's conference presentation, Nov 16, 2020
Slide 1: Investival Showcase
INVESTIVAL SHOWCASE F.R. Martelet, M.D., CEO 11-16 November 2020 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Oasmia – an innovation-focused specialty pharmaceutical company
Oasmia – an innovation-focused specialty pharmaceutical company NASDAQ Stockholm 2010 Agile, flexible structure, Market Cap approx. SEK 2,0 B Solid cash position XR-17™ technology platform R&D-focused Production Enhances the intravenous delivery of established and novel drugs in Facility in Uppsala,
Slide 4: The new team leading Oasmia's transformation
The new team leading Oasmia’s transformation FRANCOIS MARTELET, M.D., Master’s Degree Business FREDRIK JÄRRSTEN* ELIN TRAMPE, Chief Executive Officer Chief Finance Officer Chief Technical Previous experience: Officer CEO in Biotechnology/ BioPharma in UK, Denmark, US and senior executive global REIN
Slide 5: Meeting the challenges of poor drug solubility
Meeting the challenges of poor drug solubility POOR API1 c.40% OF APPROVED FACTOR IN SERIOUS $180 bn SOLUBILITY DRUGS AFFECTED2 ADVERSE EVENTS (SAEs) SPENT ON PHARMA R&D EVERY YEAR 3 Solubility enhancers Major challenge in 70-90% of pipeline can cause SAEs and drug development drugs classed as / or
Slide 6: XR-17 powerful platform that can increase solubility of insoluble compounds
XR-17™ powerful platform that can increase solubility of insoluble compounds Active Pharmaceutical Ingredient (API) XR-17™ XR-17™ + API Hydrophilic head WATER INSOLUBLE Hydrophobic chain WATER SOLUBLE XR-17™ increases small molecule solubility and potentially improves safety and efficacy of new form
Slide 7: XR-17 – validated platform applicable in many therapeutic areas
XR-17™ – validated platform applicable in many therapeutic areas Drug load capacity, enabling Strong, validated safety in cancer high drug delivery capability indication1 No mandatory or limited need for pre- Shorter infusion time1,2 medication1 Superior solubility compared with Free from alcohol, C
Slide 8: Building a diverse portfolio based on XR-17 platform technology
Building a diverse portfolio based on XR-17™ platform technology Registration / Commercial Product Indication Pre-clinical Phase I Phase II Phase III approval Launch Geography Human Health Portfolio Apealea® / Ovarian cancer Pre-NDA meeting USA Paclical® (paclitaxel) Ovarian cancer EU / EEA Docetaxe
Slide 9: Apealea – offering an improved treatment option
Apealea® – offering an improved treatment option Current standard of care in ovarian cancer is carboplatin + paclitaxel Approved in EU/EEA for A subset of patients cannot tolerate solvent-based paclitaxel treatment of first relapse ovarian cancer1 and in Apealea® is a solvent-free IV formulation of
Slide 10: Apealea – global partnership worth up to $698m + royalties
Apealea® – global partnership worth up to $698m + royalties Agreement with US-based Elevar Therapeutics, subsidiary of South Korea’s HLB % Double-digit royalties on global Apealea® sales Milestones based on regulatory and sales $678M achievements Oasmia retains sole control over development of XR-17
Slide 11: Apealea – large market opportunity in ovarian cancer
Apealea® – large market opportunity in ovarian cancer 1 Annual ovarian cancer incidence in key territories and regions 26,600 663,000* 24,500 70% of women have a relapse three years after diagnosis2 295,000 women diagnosed in 2018 Platinum analogs used alone or in combination with paclitaxel are the
Slide 12: Oasmia's strategy
Oasmia’s strategy 1 2 3 4 Execute on Apealea® Partnering & clinical Clinical development In / out-licensing, global partnership with development with of Docetaxel micellar partnering & M&A in Elevar Therapeutics XR-17™ / XR-19 and new API oncology platforms Commercialization deal Evaluate poorly wat
Slide 13: Oasmia – multiple catalysts and investment drivers
Oasmia – multiple catalysts and investment drivers Potential near and mid-term value drivers Investment drivers • Elevar partnering for Apealea® in Europe, Asia • Commercial-stage company with proven capabilities • Apealea® royalties • Validated XR-17™ technology platform • Docetaxel micellar Phase